I’m glad you reached out about Farxiga (dapagliflozin). Predicting a precise retail price for 2026 is a bit of a guessing game—drug prices are shaped by a whole mix of factors: patent status, insurance negotiations, generic competition, health‑policy changes, and even the manufacturer’s own pricing strategy. That said, I can give you a snapshot of what’s happening now and the trends that are likely to play out, which should help you gauge what to expect in a few years.
1. What the numbers look like today (2024)
| Price metric |
Typical value |
Notes |
| U.S. list price (average wholesale price, AWP) |
≈ $600–$700 per month |
The “black‑box” price that you see in the drug database; insurers and pharmacy benefit managers (PBMs) negotiate lower prices. |
| Average sales price (ASP) |
≈ $520–$580 per month |
The price paid by insurers after manufacturer discounts; most insurers use this as the basis for reimbursement. |
| Out‑of‑pocket cost |
$20–$80 per month |
Depends on your insurance deductible, copay tiers, and whether you’re on a specialty pharmacy program. |
These numbers are averages. The exact cost you see will be influenced by your insurance plan’s formulary tier and the specific PBM contracts your insurer has.
2. Why the price might stay relatively stable until the late 2020s
| Factor |
How it matters for Farxiga |
| Patent protection |
Farxiga’s patents (including formulation and method‑of‑use patents) expire in 2033–2034. Until then, no generic copies are allowed, so the brand price is essentially “locked in” except for incremental manufacturer pricing changes. |
| Manufacturer pricing strategy |
Pfizer (the current licensee) has historically maintained a fairly steady price for the brand, occasionally bumping it up with new indications or incremental formulation changes. |
| Competitive landscape |
SGLT‑2 inhibitors (e.g., Jardiance, Empagliflozin, Invokana) are already on the market, so Farxiga’s pricing is partly competitive. But the absence of generics keeps the brand price high relative to a generic launch. |
| Regulatory & policy pressure |
The U.S. federal and state governments have been pushing for drug‑price transparency and negotiation, but full price‑cut legislation for brand drugs is still pending. So the price will likely adjust gradually rather than in a single blow. |
Bottom line: Until a generic version (or a “biosimilar” equivalent, though that’s not common for small molecules) hits the market, the brand price will probably move in line with modest inflation adjustments or new indications.
3. What could lower the price in 2026?
-
Generic launch
If a generic dapagliflozin becomes available before the 2033 patent expiration (e.g., through a “patent‑in‑fringe” strategy), you could see the price drop dramatically—often to 10–30 % of the brand’s AWP. However, such an early generic launch is unlikely without a major legal challenge.
-
Insurance formulary shifts
If your insurer moves Farxiga to a lower copay tier or offers a “step‑down” program (encouraging patients to switch to generics or other SGLT‑2 inhibitors), your out‑of‑pocket cost could fall.
-
Manufacturer price reductions
Pfizer may decide to cut the list price in response to competitive pressure or public‑policy demands. In the past, they’ve reduced prices by 5–15 % for brand drugs that face stiff competition.
-
Policy changes
• 2025–2026 may see new federal policies that allow Medicare Part D plans to negotiate prices for certain drugs. If Farxiga falls into that category, the negotiated price could be lower than the current ASP.
• State-level price‑control legislation in places like California or New York could also influence the cost.
4. How to prepare for the future
| Tip |
Why it matters |
| Check your formulary |
Even if the list price stays high, your plan might cover Farxiga at a lower copay. |
| Ask about discount cards |
Pfizer offers patient assistance and discount programs for those with qualifying income levels. |
| Consider the “switch” option |
If you’re comfortable with another SGLT‑2 inhibitor (like Jardiance or Empagliflozin), your insurance might cover it at a lower copay tier. |
| Stay updated on policy changes |
Subscribe to newsletters from the FDA, CMS, or your insurer’s patient portal to catch any upcoming price negotiations. |
5. Bottom line estimate (2026)
| Scenario |
Approximate cost |
| Brand price unchanged (no generics) |
$600–$650/month (AWP) – $520–$580/month (ASP) |
| Manufacturer price cut (5–10 %) |
$540–$600/month (AWP) – $470–$530/month (ASP) |
| Generic launch (unlikely before 2033) |
$60–$120/month (estimated for a generic) |
Key takeaway: In 2026, you should expect Farxiga’s brand price to hover in the $520–$650/month range, with your out‑of‑pocket cost determined by your insurance contract. The price is unlikely to drop dramatically unless a generic becomes available or a major policy shift forces a discount.
If you’re looking for a precise number for a specific insurance plan or a different country, let me know the details (e.g., your insurance carrier, deductible, or if you’re in the U.S., U.K., or elsewhere). I can pull in more localized pricing data for you.